e-eso

19th ESO-ESMO Masterclass in Clinical Oncology

Programme

MCO Coordinator: N Pavlidis, GR

ESO Chair: F. A. Peccatori, IT

ESMO Chair: F. Lordick, DE

Host Chair: E. Felip, ES

Scientific Advisors: C. Sessa, CH - R. A. Stahel, CH

The 19th ESO-ESMO Masterclass in Clinical Oncology is a closed event for selected participants.

Applications for this edition are closed. Applications for the 2022 edition will open soon.

Aims, objectives and teaching format

The Masterclass is a full immersion, clinical oriented event designed for medical and clinical oncologists focusing on multidisciplinarity. The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training.

It offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines. Participants will deliver case presentations within tumour boards and discuss them with an international faculty of top experts of each tumour type.

The Masterclass will be entirely in English and fluency in English is necessary for admission.

IMPORTANT INFORMATION

The Online Masterclass will be carried out in two different parts:

Part 1

Pre-recorded sessions will be made available from 5th February 2021 via this website, and will remain available for 1 month. You will be able to see all the sessions in your own time.

The pre-recorded sessions must be viewed before the Part 2 (Live weekend).

When you finish watching a block on a specific tumour, please click on the link in each session and send us up to 3 questions related to the session. Some of your questions will be selected and answered during part 2 in the Q&A sessions.

Part 2

Live sessions will be held on Saturday 6th and 7th March 2021.

During the live session, a lecture will be delivered for each main tumour group and will cover topics of interest for oncologists working in Western-Central Europe. Each lecture will be followed by a Q&A session using some of the questions that were sent in part 1.

After the Q&A session, participants will present their clinical cases, which will be discussed by the experts.

Accreditation

Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certificate that will be issued by email.

Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and 27 CME credits have been granted to this event. The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.

Application for CME recognition has been submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation, and 24 ESMO MORA cat. 1 credits have been granted to this event.

ESCO - The ESO College

Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.

A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits.

Full and active participation in the Masterclass earns participants 30 ESCO credits.

Visit www.ESCO.org for more information on how to join ESCO.

Social media

Use the hashtag #ESOexperience and follow us on Facebook, Twitter and Instagram: @esoncology

Should you have any queries, please do not hesitate to contact the event organisers:

Alice Ciocchini - Organisation and Programme - aciocchini@eso.net

Corinne Hall - Applications and Organisation - chall@eso.net

Mariachiara Deleo - e-ESO Assistant - mdeleo@eso.net

Francesca Marangoni - e-ESO Executive Manager - fmarangoni@eso.net

The Masterclass in Clinical Oncology is an ESO-ESMO joint event

The 2021 Masterclass is part of the Masterclass-Online Study Program in Advanced Oncology of the University of Ulm

Communication skills workshop organised by
ABC Global Alliance

Faculty list

Conflict of interest

How to enable pop-ups

Share on:

Expert: Florian Lordick

Breast Cancer

Parp inhibitors in BRCA mutation carriers

Expert: Giuseppe Curigliano

Q&A session

Expert: Giuseppe Curigliano

Expert: Olivia Pagani

Expert: Giancarlo Pruneri

Expert: Maria-João Cardoso

Q&A session

Expert: Karim Fizazi

Expert: Xavier Maldonado

Expert: Ursula Vogl

Expert: Bertrand Tombal

Expert: Thi Dan Linh Nguyen-Kim

Q&A session

Expert: Thi Dan Linh Nguyen-Kim

Expert: Enriqueta Felip

Expert: Fiona McDonald

Gynaecological Cancers

The role of mutation testing in gynaecological cancer

Expert: Susana Banerjee

Q&A session

Expert: Jan Baptist Vermorken

Expert: Susana Banerjee

Lung cancer - Clinical case discussion Group A

Expert: Thi Dan Linh Nguyen-Kim

Expert: Enriqueta Felip

Expert: Fiona McDonald

Gynaecological cancers - Clinical case discussion Group B

Expert: Jan Baptist Vermorken

Expert: Susana Banerjee

Gastro-intestinal Cancers

Biomarkers for precision treatment in gastrointestinal tumors

Expert: Hanneke van Laarhoven

Q&A session

Expert: Hanneke van Laarhoven

Expert: Sara De Dosso

Expert: Florian Lordick

19th ESO-ESMO Masterclass in Clinical Oncology

Programme

Clinical Sessions - Breast Cancer (LECTURES)

Molecular diagnostic pathology

Current controversies and challenges in breast cancer surgery

Current controversies and challenges in radiotherapy

Preoperative chemotherapy and biologicals

Systemic treatment of luminal early and advanced breast cancer

Systemic treatment of early and advanced triple negative disease

Systemic treatment of HER2+ early and advanced disease

Optimal approach in locally advanced disease: ESO-ESMO ABC Guidelines

Clinical Sessions - Lung Cancer (LECTURES)

Molecular diagnostic pathology of NSCLC

Systemic therapy for NSCLC without oncogenic driver mutations

Systemic therapy for NSCLC with oncogenic driver mutations

Radiotherapy for NSCLC

Surgery for early and locally advanced NSCLC

Multimodality treatment of stage III NSCLC

Multimodality treatment of SCLC

Clinical Sessions - Gastrointestinal Cancer (LECTURES)

Adjuvant treatment in colon cancer

Systemic treatment in advanced colorectal cancer

Multimodal management of localized rectal cancer

Systemic treatment in advanced esophageal and gastric cancer

Management of pancreatic cancer

Optimal sequencing of systemic treatment for advanced hepatocellular carcinoma

Liquid biopsies in GI tumors

Clinical Sessions - Gyneacological Cancer (LECTURES)

Systemic management of ovarian cancer and inhibitors of Parp

Systemic treatment in cervical and endometrial cancer

Guidelines in endometrial cancer

Clinical Sessions - Genitourinary Cancer (LECTURES)

Systemic treatment of bladder cancer

First line endocrine therapy in endocrine sensitive prostate cancer

Treatment of endocrine resistant and refractory prostate cancer

Localized prostate cancer

Metastatic renal cancer: evidence-based treatment

Management of testicular cancer

Spotlights session (LECTURES)

Cancer patients with COVID-19

Communication skills

Ethics issues

Immuno-oncology

Cancer in the elderly

Breast cancer during pregnancy and fertility preservation

Early integration in oncology, supportive and palliative care

Nutrition

Genomic Tests in clinical practice

Day 1 (LIVE) - Breast cancer and Genitourinary cancer

Welcome by ESO and ESMO Live streaming on 06 March 2021 at 08:30 CET

Breast Cancer

Breast Cancer - Clinical case discussion Group A

Breast Cancer - Clinical case discussion Group B

Genitourinary Cancer

Genitourinary Cancer - Clinical case discussion Group A

Genitourinary Cancer - Clinical case discussion Group B

Day 2 (LIVE) - Lung, Gynaecological and Gastro-intestinal Cancers

Lung Cancer Live streaming on 07 March 2021 at 08:30 CET

Gynaecological Cancers

Lung cancer - Clinical case discussion Group A

Gynaecological cancers - Clinical case discussion Group B

Gastro-intestinal Cancers

Gastro-intestinal Cancers - Clinical case discussion Group A

Gastro-intestinal Cancers - Clinical case discussion Group B

Closing remarks and awards